|

EXFOLIATION
(PSEUDOEXFOLIATION) SYNDROME
Robert
Ritch, M.D.
Exfoliation syndrome (XFS) is characterized by the production and
progressive accumulation of a fibrillar extracellular material in many
ocular tissues. When averaged across the globe, it is the most common
identifiable cause of glaucoma worldwide, and in some countries accounts
for the majority of glaucoma. It leads to both open angle glaucoma and
angle-closure glaucoma, and has been causatively associated with
cataract, lens dislocation, and central retinal vein occlusion. Eyes
with XFS have a greater frequency of complications at the time of
cataract extraction, such as zonular dialysis, capsular rupture, and
vitreous loss. Based on the identification of accumulations in orbital
tissues, skin specimens, and visceral organs, XFS appears to be a
generalized disorder of the extracellular matrix. The potential
ramifications of this disorder appear to be far more important than ever
before realized. Two reviews of XFS have appeared in the past year.
47,
62
Epidemiology
XFS
occurs worldwide, although reported prevalence rates vary extensively.
This reflects a combination of true differences due to racial, ethnic,
or other as-yet-unknown reasons; the age and sex distribution of the
patients or population group examined; the clinical criteria used to
diagnose XFS; the ability of the examiner to detect early stages; the
thoroughness of the examination; and the awareness of the observer.
1
Recent studies in some countries, such as Spain and Hungary, suggest
literally an order of magnitude higher prevalence of XFS in the
population and in glaucoma patients than reported 30-40 years ago. This
obviously represents improvement in the ability to look for and identify
the material clinically.
In
Scandinavia, where XFS was first described, the highest rates in studies
of persons over age 60 have been reported from Iceland (about 25%),
8,
59
and
Finland (over 20%)
8,
25, 26
Rates
in Norway and Sweden average about half these, while those in Denmark
have been reported to be much less. Russian Jewish immigrants to the
United States also have a very high prevalence of XFS.
30
XFS
is also very common in Ireland, the Middle East, India, and Japan.
The
prevalence of XFS may also vary within countries in similar environments
and over short distances. Differences among ethnically homogeneous
persons or between ethnic groups living in close proximity might lead to
useful investigations. In four prefectures in Crete, Kozobolis et al
24
found
XFS in persons over age 40 to range from 11.5% to 27%. In France, the
overall prevalence over age 70 (in a report by several observers) is
about 5.5%, ranging from 20.6% in Brest, to 3.6% in Toulon. 4,
5
Ringvold et al 44 found
rates of 10.2%, 19.6%, and 21.0% in three closely situated
municipalities in central Norway. In New Mexico, Spanish-American men
are nearly six times as likely to develop XFS than are
non-Spanish-Americans. 17
XFS increases in prevalence with age. Men and women are probably
equally affects. In the United States, whites are affected much more
often than African-Americans. Genetic factors predisposing to
susceptibility have barely begun to be explored, and no clear hereditary
pattern has been identified. One study found a ninefold increase in
prevalence in first degree relatives over age 40 compared to the general
population, 2 suggesting autosomal dominant inheritance. A preponderance of maternal
transmission of XFS in families reported has raised the possibility of
mitochondrial inheritance. 6
Glaucoma
occurs more commonly in eyes with XFS than in those without it. Elevated
IOP with or without glaucomatous damage occurs in approximately 25% of
persons with XFS, or about 6 to 10 times the rate in eyes without XFS.
Exfoliative glaucoma has a more serious clinical course and worse
prognosis than primary open-angle glaucoma. There is a significantly
higher frequency and severity of optic nerve damage at the time of
diagnosis, worse visual field damage, poorer response to medications,
more severe clinical course, and more frequent necessity for surgical
intervention. Persons with elevated IOP and XFS are much more likely to
develop glaucomatous damage on long-term follow-up than are those
without XFS.
XFS
is the only common glaucoma which usually affects only one eye or
affects one eye long in advance of the other. As a rule of thumb, anyone
over age 50 with unilateral glaucoma should be suspected of having XFS.
The terms "unilateral" and "monocular" are
misleading. When only one eye is clinically involved, the fellow eye
often has abnormal aqueous humor dynamics or glaucomatous damage. Since
early pigment-related signs of XFS are found in the majority of
unaffected fellow eyes, and since exfoliation fibers may be detected on
conjunctival biopsy in virtually all unaffected fellow eyes, these cases
are actually asymmetric. 12,
41
Clinical
Findings
Lens:
Deposits of white material on the anterior lens surface are the most
consistent and important diagnostic feature of XFS. The classic pattern
consists of three zones: a central disc corresponding roughly to the
diameter of the pupil; a granular, often layered, peripheral zone, and a
clear area separating the two (Figure 1). The central zone is a
homogeneous, white sheet and is often absent, while the peripheral zone
is always present (Figure 2). The clear zone is created by rubbing of
the iris over the surface of the lens during pupillary movement.
Phacodonesis, or looseness of the lens because of damage to the zonules
which hold the lens in place, is common and is one of the leading
factors predisposing to an increase in complications at the time of
cataract surgery. Spontaneous partial or complete dislocation of the
lens can occur (Figure 3).
Iris:
Iris changes are an early and well recognized clinical feature in
XFS. Next to the lens, exfoliation material is most prominent at the
pupillary border (Figure 4). Pigment loss from the iris sphincter region
and its deposition on anterior chamber structures is a hallmark of XFS.
Loss of iris pigment and its deposition throughout the anterior segment
are reflected in iris sphincter region transillumination defects (Figure
5), loss of the pupillary ruff (Figure 6), pigment dispersion in the
anterior chamber after pupillary dilation (Figure 7), pigment deposition
on the iris surface, increased trabecular meshwork pigmentation (Figure
8), and pigment deposition on the iris surface. 40
The blood vessels of the iris are often narrowed and may become
obliterated. In advanced stages, the cells of the vessel wall degenerate
completely. Fluorescein angiographic studies have shown partial
occlusion of radial iris capillaries associated with hypoperfusion, a
reduced number of vessels, formation of tiny new blood vessels, and
diffuse, patchy fluorescein dye leakage.
Cornea:
Flakes of exfoliation material may be present on the endothelium. There
may be a diffuse, nonspecific pigmentation of the central endothelium,
occasionally having the pattern of a Krukenberg spindle. Pigment is
characteristically deposited on Schwalbe's line and sometimes as a wavy
line or lines anterior to Schwalbe's line (Sampaolesi line, Figure 8).
The number of corneal endothelial cells is reduced and central corneal
thickness is also greater in eyes with XFS, perhaps reflecting early
corneal dysfunction. 43 These
changes predispose to early corneal decompensation at only moderate
rises of IOP or after cataract surgery. 35
Other
findings: Eyes with XFS often dilate poorly. Exfoliation material
may be detected earliest on the ciliary processes and zonules, which are
often frayed and broken. Abnormal zonular attachment to the lens or
ciliary body may account for the development of lens subluxation or
dislocation. Deposits of exfoliation material cover the crests of the
ciliary processes in the pars plicata.
Increased
trabecular pigmentation is a prominent sign of XFS and is apparent in
virtually all patients with clinically evident disease. The distribution
of the pigment tends to be uneven or splotchy and, in clinically
unilateral cases, is almost always denser in the involved eye. There
appears to be a highly significant correlation between elevated IOP and
the degree of pigmentation of the meshwork. 33 In
virtually all studies of patients with unilateral involvement, the
trabecular pigment is almost always denser in the involved eye.27,
46 Eyes
with exfoliative glaucoma tend to have greater pigmentation than eyes
with XFS but without glaucoma. 42,
50 and
eyes with exfoliative glaucoma have greater pigmentation than eyes with
COAG.9,
19 Marked IOP rises can occur in eyes with XFS after dilation for retinal
examination. Post-dilation IOPs should be checked routinely and the
anterior chamber examined for pigment liberation in all patients
receiving dilating drops.
Ocular
Associations: Increasing evidence suggests an causal association
between XFS and cataract formation. The iris pigment epithelium and the
lens surface, both coated with exfoliation material, tend to adhere
(posterior synechiae), particularly when pupillary movement is inhibited
by miotic therapy (Figure 9). Vigorous dilation can result in adhesion
of the entire iris pigment epithelium onto the lens surface.
Patients with XFS are much more prone to have complications at
the time of cataract extraction. Eyes with XFS dilate less well and have
greater incidences of capsular rupture, zonular dehiscence, and vitreous
loss. Pupillary diameter and zonular fragility have been suggested as
the most important risk factors for capsular rupture and vitreous loss.
Zonular fragility increases the risk of lens dislocation, zonular
dialysis, or vitreous loss up to ten times. 11,
34, 36, 57
Postoperative complications of posterior capsular opacification, capsule
contraction syndrome, intraocular lens decentration, and inflammation
are also greater in eyes with XFS.
A possible association of XFS with retinal vein occlusion has
also been suggested. 18,
31, 38 In
clinically unilateral cases of XFS, ipsilateral pulsatile ocular blood
flow 56 and
carotid blood flow 53 have
been reported to be reduced. Eyes may be more prone to developing dry
eye syndrome, especially if treated with beta-adrenergic blocking
agents. 23
Extraocular
findings: Aggregates of exfoliation fibers have been identified in
skin and in autopsy specimens of heart, lung, liver, kidney, gall
bladder, and cerebral meninges in two patients with ocular XFS. 51,
58 The
deposits were focally present in the interstitial fibrovascular
connective tissue septa of these organs, frequently adjacent to elastic
fibers, elastic microfibrils, collagen fibers, fibroblasts, and to the
walls of small blood vessels.
In the Blue Mountains Eye Study (Australia), XFS correlated
positively with a history of hypertension, angina, myocardial infarction
or stroke, suggestive of vascular effects of the disease. 32 In
another study, 50% of persons with XFS had cardiovascular disease, three
times the rate of the unaffected subjects. 7 In
another study, XFS was significantly associated with aneurysms of the
abdominal aorta, but not with carotid artery occlusion. 52 Nevertheless, no increase in mortality in patients with XFS has been
reported. 45,
55
Mechanisms
of Glaucoma
Open-angle
glaucoma: Potential causes of elevated IOP in eyes with XFS include
trabecular cell dysfunction, blockage of the meshwork by exogenous and
endogenous exfoliation material, blockage of the meshwork by liberated
iris pigment, trabecular cell dysfunction, and coexisting primary
open-angle glaucoma. Obstruction of the trabecular meshwork either by
pigment or exfoliation material or both is generally considered the most
likely cause. Exfoliation syndrome can develop later in life in patients
who have had bilateral pigment dispersion syndrome, and the presentation
of an older patient with signs of bilateral pigment dispersion and
unilateral glaucoma warrants a careful examination for the development
of XFS. 28,
48, 61
Angle-closure
glaucoma: Although two important series noted a high incidence of
narrow or occludable angles in eyes with XFS, 29,
63 angle-closure glaucoma was until recently considered rare in patients
with XFS and was usually thought to be coincidental. Ritch 46 found
either clinically apparent XFS or exfoliation material on conjunctival
biopsy in 17 of 60 (28.3%) consecutive patients with uncomplicated
primary ACG or occludable angles. In another study, 5 of 18 affected
patients had occludable angles. 7 Characteristics of eyes with XFS which predispose to angle-closure
glaucoma include the predisposition to posterior synechia formation,
zonular weakness and associated forward lens movement, iris stiffness
and rigidity, and a smaller pupil. Patients with ACG or occludable
angles and XFS tend to be more myopic and to have deeper anterior
chambers than those without XFS.
Management
Glaucoma associated with XFS tends to respond less well to
medical therapy than does POAG. Apraclonidine is additive to timolol in
eyes with XFS and elevated IOP. 22
Dorzolamide is almost as effective as timolol and also is additive with
it. 13,
21
Cholinergic agents are effective and probably have a greater additive
effect with beta-blockers in XFS than in POAG. Not only do miotics lower
IOP, but should enable the meshwork to clear more rapidly by increasing
aqueous outflow and should slow the progression of the disease by
limiting pupillary movement. Becker 3 has
presented suggestive evidence that treatment with aqueous suppressants
leads to worsening of trabecular function.
Argon laser trabeculoplasty (ALT) is particularly effective,
at least early on, in eyes with XFS. The baseline IOP is usually higher
than in eyes with POAG undergoing ALT and the initial drop in IOP is
greater. Approximately 20% of patients develop sudden, late rises of IOP
within the first two years after treatment. 37,
49
Continued pigment liberation may overwhelm the restored functional
capacity of the trabecular meshwork, and maintenance miotic therapy to
minimize papillary movement after ALT might counteract this. The
increased effectiveness may be related to the increased trabecular
meshwork pigmentation found in XFS. Long-term success drops to
approximately 35-55% at 3-6 years.
The results of trabeculectomy are comparable to those in POAG,
but complications are more frequent. IOP after trabeculectomy has been
reported to be lower in eyes with exfoliative glaucoma than in eyes with
POAG. 20,
39, 54
Trabeculotomy has been reported to have success rates of 79% at 3 years
and 64% at 5 years, with medication. 60
Jacobi and Krieglstein 14 have
presented a procedure termed trabecular aspiration, designed to improve
outflow facility. Trabecular aspiration combined with
phacoemulsification was significantly more effective than cataract
surgery alone in reducing postoperative IOP and the necessity for
antiglaucoma medication. 10,
15
However, it is less effective than phacoemulsification combined with
trabeculectomy. 16
References
1. Aasved H: The geographical distribution of fibrillopathia
epitheliocapsularis Acta Ophthalmol 47:792-810, 1969.
2. Aasved H: Study of relatives of persons with fibrillopathia
epitheliocapsularis (pseudoexfoliation of the lens capsule) Acta
Ophthalmol 53:879-886, 1975.
3.
Becker B: Does hyposecretion of aqueous humor damage the
trabecular meshwork? (editorial) J Glaucoma 4:303-305, 1995.
4.
Colin J, Bonissent JF, Resnikoff S. Epidemiology of the
exfoliation syndrome. 17th Congr Europ Soc Ophthalmol.
Helsinki: , 1985: 230-231.
5.
Colin J, Le Gall G, Le Jeune B, et al: The prevalence of
exfoliation syndrome in different areas of France Acta Ophthalmol
66(Suppl 184):86-89, 1988.
6.
Damji KF: Is pseudoexfoliation syndrome inherited? A review of
genetic and nongenetic factors and a new observation Ophthalmic Genetics
19:175-185, 1998.
7.
Damji KF, Bains HS, Amjadi K, et al: Familial occurrence of
pseudoexfoliation in Canada Can J Ophthalmol 34:257-265, 1999.
8.
Forsius H: Prevalence of pseudoexfoliation of the lens in Finns,
Lapps, Icelanders, Eskimos, and Russians Trans Ophthalmol Soc UK
99:296-298, 1979.
9.
Futa R, Shimizu T, Furuyoshi N: Clinical features of capsular
glaucoma in comparison with primary open-angle glaucoma in Japan Acta
Ophthalmol 70:214-219, 1992.
10.
Georgopoulos GT, Chalkiadakis J, Livir-Rallatos G, et al:
Combined clear cornea phacoemulsification and trabecular apsiration in
the treatment of pseudoexfoliative glaucoma associated with cataract
Graefes Arch Clin Exp Ophthalmol 238:816-821, 2000.
11.
Goder GJ: Our experiences in planned extracapsular cataract
extraction in the exfoliation syndrome Acta Ophthalmol 66(Suppl
184):126-128, 1988.
12.
Hammer T, Schlötzer-Schrehardt U, Naumann GOH: Unilateral or
asymmetric pseudoexfoliation syndrome? An ultrastructural study Arch
Ophthalmol in press, 2001.
13.
Heijl A, Strahlman E, Sverrisson T, et al: A comparison of
dorzolamide and timolol in patients with pseudoexfoliation and glaucoma
or ocular hypertension Ophthalmology 104:137-142, 1997.
14.
Jacobi PC, Dietlein TS, Krieglstein GK: Bimanual trabecular
aspiration in pseudoexfoliation glaucoma-an alternative in nonfiltering
glaucoma surgery Ophthalmology 105:886-894, 1998.
15.
Jacobi PC, Dietlein TS, Krieglstein GK: Comparative study of
trabecular aspiration versus trabeculectomy in glaucoma triple procedure
to treat pseudoexfoliation glaucoma Arch Ophthalmol 117:1311-1318, 1999.
16.
Jacobi PC, Dietlein TS, Krieglstein GK: The risk profile of
trabecular aspiration versus trabeculectomy in glaucoma triple procedure
Graefes Arch Clin Exp Ophthalmol 238:545-551, 2000.
17.
Jones W, White RE, Magnus DE: Increased occurrence of exfoliation
in the male, Spanish American population of New Mexico J Am Optom Assoc
63:643-648, 1992.
18.
Karjalainen K, Tarkkanen A, Merenmies L: Exfoliation syndrome in
enucleated haemorrhagic and absolute glaucoma Acta Ophthalmol
65:320-322, 1987.
19.
Konstas AGP, Dutton GN: Gonioscopic findings in Greek patients
with exfoliation glaucoma Acta Ophthalmol 69:281-287, 1991.
20.
Konstas AGP, Jay JL, Marshall GE, et al: Prevalence, diagnostic
features, and response to trabeculectomy in exfoliation glaucoma
Ophthalmology 100:619-627, 1993.
21.
Konstas AGP, Maltezos A, Bufidis T, et al: Twenty-four hour
control of intraocular pressure with dorzolamide and timolol maleate in
exfoliaiton and primary open-angle glaucoma Eye 14:73-77, 2000.
22.
Konstas AGP, Maltezos A, Mantziris DA, et al: The comparative
ocular hypotensive effects of apraclonidine with timolol maleate in
exfoliation versus primary open-angle glaucoma patients Eye 13:314-318,
1999.
23.
Kozobolis VP, Detorakis ET, Tsopakis GM, et al: Evaluation of
tear secretion and tear film stability in pseudoexfoliation syndrome
Acta Ophthalmol Scand 77:406-409, 1999.
24.
Kozobolis VP, Papatzanaki M, Vlachonikolis IG, et al:
Epidemiology of pseudoexfoliation in the island of Crete (Greece) Acta
Ophthalmol 75:726-729, 1997.
25.
Krause U: Frequency of capsular glaucoma in central Finland Acta
Ophthalmol 51:235-240, 1973.
26.
Krause U, Alanko HI, Kärmä J, et al: Prevalence of exfoliation
syndrome in Finland Acta Ophthalmol 66(Suppl 184):120-122, 1988.
27.
Kunishi Y, Kunishi M, Yoshino H, et al: Gonioscopic features of
pseudoexfoliation Jpn J Clin Ophthalmol 52:1683-1689, 1998.
28.
Layden WE, Ritch R, King DG, et al: Combined exfoliation and
pigment dispersion syndromes Am J Ophthalmol 109:530-534, 1990.
29.
Layden WE, Shaffer RN: Exfoliation syndrome Am J Ophthalmol
78:835-841, 1974.
30.
Levey SB, Wahl SM, Abrams DA, et al: Pseudoexfoliation syndrome
in the Russian immigrant population Ann Ophthalmol 27:366-368, 1995.
31.
Meyer E, et al: Pseudoexfoliation: Epidemiology, clinical and
scanning electron microscopic study Ophthalmologica 188:141-147, 1984.
32.
Mitchell P, Wang JJ, Smith W: Association of pseudoexfoliation
with increased vascular risk Am J Ophthalmol 124:685-687, 1997.
33.
Moreno-Montañés J, Quintero Alonso A, Alvarez Serna A, et al:
Pseudoexfoliation syndrome: clinical study of the anterior chamber angle
J Fr Ophtalmol 13:183-188, 1990.
34.
Naumann GOH, Küchle M, Schonherr U: Pseudoexfoliation as a risk
factor for vitreous loss in extracapsular cataract extraction Fortschr
Ophthalmol 86:543-545, 1989.
35.
Naumann GOH, Schlötzer-Schrehardt U: Keratopathy in
pseudoexfoliation syndrome as a cause of corneal endothelial
decompensation. A clinicopathologic study Ophthalmology 107:1111-1124,
2000.
36.
Naumann GOH, the "Erlanger Augenblätter-Group":
Exfoliation syndrome as a risk factor for vitreous loss in extracapsular
cataract surgery Acta Ophthalmol 66 (Suppl 184):129-131, 1988.
37.
Pohjanpelto P: Late results of laser trabeculoplasty for
increased intraocular pressure Acta Ophthalmol 61:998, 1983.
38.
Pohjanpelto P: Long-term prognosis of visual field in glaucoma
simplex and glaucoma capsulare Acta Ophthalmol 63:418-423, 1985.
39.
Popovic V, Sjostrand J: Course of exfoliation and simplex
glaucoma after primary trabeculectomy Br J Ophthalmol 83:305-310, 1999.
40.
Prince AM, Ritch R: Clinical signs of the pseudoexfoliation
syndrome Ophthalmology 93:803-807, 1986.
41.
Prince AM, Streeten BW, Ritch R, et al: Preclinical diagnosis of
pseudoexfoliation syndrome Arch Ophthalmol 105:1076-1082, 1987.
42.
Puska P: The amount of lens exfoliation and chamber-angle
pigmentation in exfoliation syndrome with or without glaucoma Acta
Ophthalmol 73:226-232, 1995.
43.
Puska P, Vasara K, Harju M, et al: Corneal thickness and corneal
endothelium in normotensive subjects with unilateral exfoliation
syndrome Graefes Arch Clin Exp Ophthalmol 238:659-663, 2000.
44.
Ringvold A, Blika S, Elsås T, et al: The prevalence of
pseudoexfoliation in three separate municipalities of Middle-Norway Acta
Ophthalmol 65(Suppl 182):17-20, 1988.
45.
Ringvold A, Blika S, Sandvik L: Pseudo-exfoliation and mortality
Acta Ophthalmol 75:255-256, 1997.
46.
Ritch R: Exfoliation syndrome: `s and occurrence
in patients with occludable angles Trans Am Ophthalmol Soc 92:845-944,
1994.
47.
Ritch R: Exfoliation syndrome Curr Opin Ophthalmol 12:124-130,
2001.
48.
Ritch R, Mudumbai R, Liebmann JM: Combined exfoliation and
pigment dispersion: An overlap syndrome Ophthalmology 107:1004-1008,
2000.
49.
Ritch R, Podos SM: Laser trabeculoplasty in exfoliation syndrome
Bull NY Acad Med 59:339-344, 1983.
50.
Rouhiainen H, Teräsvirta M: Pigmentation of the anterior chamber
angle in normal and pseudoexfoliative eyes Acta Ophthalmol 68:700-702,
1990.
51.
Schlötzer-Schrehardt U, Koca MR, Naumann GOH, et al:
Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder?
Arch Ophthalmol 110:1752-1756, 1992.
52.
Schumacher S, Schloötzer-Schrehardt U, Martus P, et al:
Pseudoexfoliaiton syndrome and aneurysms of the abdominal aorta Lancet
357:359-360, 2001.
53.
Scullica L, Buceti R, Castagna I, et al: Functional aspects of
pseudoexfoliation: Physiopathological features New Trends Ophthalmol
8:163-168, 1993.
54.
Serguhn S, Spiegel D: Efficacy of trabeculectomy for
pseudoexfoliation glaucoma and primary open-angle glaucoma Klin Monatsbl
Augenheilkd 215:281-286, 1999.
55.
Shrüm KR, Hattenhauer MG, Hodge D: Cardiovascular and
cerebrovascular mortality associated with ocular pseudoexfoliation Am J
Ophthalmol 129:83-86, 2000.
56.
Sibour G, Finazzo C, Boles Carenini A: Monolateral
pseudoexfoliatio capsulae: A study of choroidal blood flow Acta
Ophthalmol Scand 75(Suppl 224):13-14, 1997.
57.
Skuta GL, Parrish RK, II, Hodapp E, et al: Zonular dialysis
during extracapsular cataract extraction in pseudoexfoliation syndrome
Arch Ophthalmol 105:632-634, 1987.
58.
Streeten BW, Li ZY, Wallace RN, et al: Pseudoexfoliative
fibrillopathy in visceral organs of a patient with pseudoexfoliation
syndrome Arch Ophthalmol 110:1757-1762, 1992.
59.
Sveinsson D: The frequency of senile exfoliation in Iceland Acta
Ophthalmol 52:596-602, 1974.
60.
Tanihara H, Negi A, Akimoto M, et al: Surgical effect of
trabeculotomy ab externo on adult eyes with primary open angle glaucoma
and pseudoexfoliation syndrome Arch Ophthalmol 111:1653-1661, 1993.
61.
Tarkkanen A, Kivela T: Unilateral capsular glaucoma after
long-standing bilateral pigmentary glaucoma Eye 13:212-214, 1999.
62.
Vesti E, Kivelä T: Exfoliation syndrome and exfoliation glaucoma
Prog Retinal Eye Res 19:345-368, 2000.
63.
Wishart PK, Spaeth GL, Poryzees EM: Anterior chamber angle in the
exfoliation syndrome Br J Ophthalmol 69:103-105, 1985.
[ About NYGRI ][ Education ][ Glaucoma Network ]
[ How You Can Help ][ Question Corner ][ Research ]
|